
PHILADELPHIA-In designing trials of potential toxicity modifiers, consideration must be given to endpoint selection and correlation of endpoints, as well as sample size and analysis methods. Important design factors were reviewed by Charles B. Scott, PhD, associate director of quality of life research at the American College of Radiology in Philadelphia.

